Highlights
- •Children with treatment-resistant epilepsy received increasing doses of cannabidiol.
- •Incidence of all and major seizures was significantly reduced over 36 months.
- •Mean increase in seizure-free days was >5 in each 28-day treatment period.
- •Cannabidiol was generally well tolerated in doses up to 50 mg/kg/day.
Abstract
Introduction
An intermediate-sized, multicenter, expanded-access study was opened in 2015 through
the support of the State of Georgia. This study provided children with treatment-resistant
epilepsy (TRE) access to plant-derived highly purified cannabidiol (CBD; Epidiolex®
in the US; Epidyolex® in the EU; 100 mg/mL oral solution). These children had failed
to achieve seizure freedom with available treatment options and were ineligible to
participate in randomized controlled trials that only included patients with Lennox–Gastaut
and Dravet syndromes.
Methods
Cannabidiol safety, changes in seizure type, frequency, and seizure-free days were
evaluated for children aged 1–18 years (at time of consent) as an adjunctive treatment
for 36 months. The study consisted of a two-month baseline period, a titration period,
treatment period, and optional titration period, which occurred after ≥26 weeks of treatment. Cannabidiol treatment was administered up to a targeted dose
of 25 mg/kg/day, with an optional secondary treatment up to 50 mg/kg/day. Daily seizure
type, seizure frequency, and seizure-free days were recorded in a Web-based diary,
and changes in these outcomes were recorded and analyzed for the duration of the study.
The occurrence of adverse events (AEs) was also recorded.
Results
The median percentage change in seizures for 45 patients in Months 3, 6, 12, 18, 24,
and 36 showed a statistically significant (p < 0.001) reduction in major seizures (ranging from 54 to 72% at various time points)
and all seizures (61–70%) compared with baseline. A mean increase in seizure-free
days per 28 days was >5 in all treatment periods after Month 2, and an average increase of 7.52 (p < 0.001) seizure-free days per 28 days was observed at the end of follow-up compared
with baseline. All patients experienced ≥1 AE. Children who transitioned to the optional secondary treatment (high-dose group)
reported more AEs before increasing their dose to >25.0 mg/kg/day compared with the low-dose group. However, the average rate of AEs
was significantly lower after moving to a high-dose regimen (p = 0.004). Twelve children reported 20 serious AEs, none of which were considered
related to CBD.
Conclusions
This study supports CBD as an adjunctive treatment for children with TRE. Treatment
was well tolerated in doses up to 50 mg/kg/day. Patients who did not achieve desired
results at a dose of ≤25.0 mg/kg/day reported more AEs when CBD dose increased to >25.0 mg/kg/day. Decreases in major seizure frequency and an increase in seizure-free
days compared with baseline were reported during treatment. This supports the efficacy
and tolerability of CBD for mixed seizure etiologies.
Abbreviations:
AED (antiepileptic drug), CBD (cannabidiol), TESAE (treatment-emergent serious adverse event), TEAE (treatment-emergent adverse event), TRE (treatment-resistant epilepsy)Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Epilepsy & BehaviorAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo.J Pharmacol Exp Ther. 2010; 332: 569-577
- Toward drugs derived from cannabis.Naturwissenschaften. 1978; 65: 174-179
- Modulation of mediotemporal and ventrostriatal function in humans by Delta9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis.Arch Gen Psychiatry. 2009; 66: 442-451
- Sudden, unexpected death in epilepsy.N Engl J Med. 2011; 365: 1801-1811
- Abbreviated report of the NIH/NINDS workshop on sudden unexpected death in epilepsy.Neurology. 2011; 76: 1932-1938
- SUDEP: what are the risk factors? Do seizures or antiepileptic drugs contribute to an increased risk?.Epilepsy Curr. 2012; 12: 131-132
- Early and late age of seizure onset have a differential impact on brain resting-state organization in temporal lobe epilepsy.Brain Topogr. 2015; 28: 113-126
- The neurodevelopmental impact of childhood-onset temporal lobe epilepsy on brain structure and function.Epilepsia. 2002; 43: 1062-1071
- Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: expanded access program results.Epilepsia. 2018; 59: 1540-1548
- Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.Lancet Neurol. 2016; 15: 270-278
- Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome.N Engl J Med. 2017; 376: 2011-2020
- Effect of cannabidiol on drop seizures in the Lennox–Gastaut syndrome.N Engl J Med. 2018; 378: 1888-1897
- Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome.Neurology. 2018; 90 (e11): e1204
- Cannabidiol in patients with seizures associated with Lennox–Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial.Lancet. 2018; 391: 1085-1096
Article info
Publication history
Published online: September 26, 2020
Accepted:
September 6,
2020
Received in revised form:
September 2,
2020
Received:
July 13,
2020
Footnotes
☆ClinicalTrials.gov Identifier: NCT02397863.
Identification
Copyright
© 2020 Published by Elsevier Inc.
